CASE REPORT

A teen with blaschkolinear tumid lupus erythematosus

Amy Shen, BS,a Jonathan M. Fisher, MD, MPH,b Lawrence F. Kuklinski, MD,c and Marcia Hogeling, MDb

Los Angeles, California

Key words: Blaschko’s lines; cutaneous lupus erythematosus; dapsone; lupus erythematosus tumidus; tumid lupus erythematosus.

INTRODUCTION

Tumid lupus erythematosus is a subtype of cutaneous lupus erythematosus described by Hoffmann in 1909. Unlike other forms of cutaneous lupus erythematosus, tumid lupus erythematosus lacks systemic involvement and often has negative autoimmune workup. Antinuclear antibody may be positive in about 10% of patients. The classic clinical presentation is characterized by erythematous, succulent, urticaria-like, non-scarring plaques most commonly affecting photosensitive areas. Tumid lupus erythematosus affects mostly adults. There are very few pediatric cases reported; most pediatric cases present on the face and/or upper portion of the body, and none involve the lower extremities. A unilateral blaschkolinear distribution is rare and has only been found in 3 adults and 1 child. We report an additional pediatric case of unilateral blaschkolinear tumid lupus erythematosus with a unique involvement of the lower extremity.

CASE REPORT

A 15-year-old girl presented to the dermatology clinic with a 2-year history of progressive erythematous, edematous papules and plaques in a linear pattern involving the left side of her body. Her previous dermatologist suspected sclerodema and referred her to our tertiary care center for further evaluation. She had a history of congenital amniotic band syndrome with multiple digit deformities. She had no family history of autoimmune disease and denied having joint pain and other systemic symptoms. On physical examination, there were violaceous dermal papules coalescing into blaschkolinear plaques extending from the upper portion of the left medial arm to the wrist (Fig 1, A), from the left side of the abdomen to the flank (Fig 1, C), and from the left posterior thigh to the lower portion of the leg (Fig 1, E). Further laboratory workup for autoimmune disease was notable for antinuclear antibody (1:320, nuclear, homogenous) and otherwise all negative for α1- , α2-globulins, antineutrophilic cytoplasmic antibody; antistreptolysin O, β1-, β2-globulin, cardiolipin (IgA, IgG, immunoglobulin M), centromere B, double-stranded DNA, γ-globulin, topoisomerase 1, Sjögren’s-syndrome-related antigen A, Sjögren’s-syndrome-related antigen B, Smith (Sm)/U1-RNP, rheumatoid factor, and C-reactive protein. C3 and C4 were within normal limits. Punch biopsy of the lesions revealed focal vacuolar interface change and mild superficial and deep perivascular and periadnexal lymphoplasmacytic inflammation (Fig 2, A-C). Alcian blue and colloidal iron staining showed increased superficial and deep interstitial mucin deposition (Fig 2, D). The histologic findings supported the diagnosis of tumid lupus erythematosus. The patient was initially started on hydroxychloroquine (200 mg daily), which was discontinued due to diarrhea. Topical treatment with mometasone (0.1% cream) and tacrolimus (0.1% ointment) for 1 year did not lead to significant improvement. The patient subsequently initiated treatment with oral dapsone

Abbreviations used:
C3: complement 3
C4: complement 4
IgA: immunoglobulin A
IgG: immunoglobulin G

From the Division of Dermatology, Department of Medicineb; and Department of Pathology,c David Geffen School of Medicine, University of California, Los Angeles.a

Funding sources: None.

IRB approval status: Not applicable.

Correspondence to: Marcia Hogeling, MD, Division of Dermatology, University of California, Los Angeles, 2001 Santa Monica Blvd, Suite 1070, Santa Monica, CA 90404. E-mail: mhogeling@mednet.ucla.edu.

JAAD Case Reports 2022;21:j-j.
2352-5126
© 2022 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.jdcr.2021.12.026
(25 mg) daily for 1 week followed by 50 mg daily and noted striking improvement after 5 months of treatment.

**DISCUSSION**

The diagnosis of tumid lupus erythematosus is based on clinical presentations confirmed by histopathology. This case demonstrated classic histologic features of tumid lupus erythematosus, including superficial and deep perivascular and periadnexal lymphocytic inflammation, increased interstitial mucin, subtle interface dermatitis, and a notable lack of basement membrane thickening and epidermal change, as would be expected.
in other forms of cutaneous lupus. A broad differential diagnosis should include other entities with dermal mucin deposition, in particular morphea, scleredema, and reactive granulomatous dermatitis. Linear morphea is more common in the pediatric population and in the early phase may show a mild increase in dermal mucin. This patient presented with a 2-year history of symptoms, and morphea would likely have progressed to indurated plaques with homogenized, dense collagen entrapping adnexal structures. Scleredema favors the upper portion of the torso and histologically is characterized by prominent mucin deposition between thickened collagen bundles with only sparse inflammation, and therefore it was not favored. Reactive granulomatous dermatitis may present as linear, cord-like bands, but biopsy would demonstrate interstitial and palisaded histiocytes and neutrophils as opposed to the periadnexal lymphocytes seen in this case. In the pediatric population, lichen striatus could also be considered in the differential diagnosis of a blashkolinear eruption and may

Fig 2. Histopathologic images of biopsy specimen from the left posterior thigh. A, Mild interface dermatitis and superficial and deep perivascular and periadnexal inflammation. (hematoxylin and eosin stain; original magnification: ×40.) B and C, Vacuolar interface dermatitis with superficial and deep periadnexal lymphoplasmocytic inflammation. (hematoxylin and eosin stain; original magnification: ×100.) D, Increased superficial and deep interstitial mucin. (Colloidal iron stain; original magnification: ×40.)
resemble tumid lupus histologically with superficial and deep periadnexal chronic inflammation. However, lichen striatus is composed of numerous coalescing flat-topped scaly papules, and there is a prominent lichenoid infiltrate at the dermoepidermal junction with numerous dyskeratotic keratinocytes and no increase in dermal mucin. Thus, blaschkolinear tumid lupus erythematosus was felt to best characterize this patient’s presentation.

At the present time, very few pediatric cases of tumid lupus erythematosus have been reported. Most previous pediatric cases involved the face and/or upper portion of the body with variable photosensitivity, and none involved the lower extremities. A blaschkolinear distribution has previously been reported in 3 adult cases and one pediatric case. In children, the blaschkolinear distribution is more commonly reported in discoid cutaneous lupus erythematosus and lupus panniculitis. In addition, the unique involvement of the lower portion of the body found in our patient shows that tumid lupus erythematosus in children can have a more extensive body involvement than previously reported.

Tumid lupus erythematosus in adults is generally treated similarly to other subtypes of cutaneous lupus erythematosus. First-line therapies are topical or intraleisonal corticosteroids, topical calcineurin inhibitors, and/or oral antimalarial drugs. Reported second-line therapies include dapsone, methotrexate, acitretin, mycophenolate mofetil, thalidomide, and rituximab. The treatment approach for the blaschkolinear distribution is the same, but it is worth noting that none of the reported blaschkolinear cases was controlled by topical treatment alone. All previous cases were treated with oral antimalarial drugs.

Table I. Literature review of blaschkolinear tumid lupus erythematosus cases

| Age group (yr) | Sex | Morphology and chronicity of lesions at initial presentation | Distribution | Treatment(s) with therapeutic effect | Attempted treatment(s) without improvement | Ref. |
|---------------|-----|-------------------------------------------------------------|--------------|--------------------------------------|-------------------------------------------|------|
| Child 4 F     |     | Wheal-like erythematous to brownish plaque in linear pattern for 1 yr | Right upper portion of the back, upper portion of the right chest, right arm and hand | Hydroxychloroquine 50 mg daily (2 mg/kg/day) in addition to intraleisonal steroid injections and topical steroids | Topical tacrolimus; topical steroids and intraleisonal triamcinolone injection (2.5 mg/mL) without hydroxychloroquine | Kim et al |
| 15 F          |     | Erythematous, edematous papules and plaques in a linear pattern for 2 yr | Left arm, left side of trunk, left leg | Oral dapsone 25 mg daily for 1 wk followed by 50 mg daily | Hydroxychloroquine 200 mg daily (stopped due to side effect); topical mometasone 0.1% cream; topical tacrolimus 0.1% ointment | Our case |
| Adult 32 F    |     | Linear papular and erythematous eruption for 3 yr | Forehead | Topical steroids (dexamethasone once a day) and hydroxychloroquine 200 mg daily. Complete resolution achieved after 2 mo* | None reported | Bouzit et al |
| 27 M          |     | Erythematous papules and plaques for 3 yr | Right arm, right posterior trunk | Intralesional corticosteroids and oral hydroxychloroquine 400 mg daily | None reported | Pacheco et al |
| 43 M          |     | Erythematous papules and plaques for 1 yr | Right side of the forehead to right eyelid | Systemic corticosteroids and hydroxychloroquine 200 mg daily | None reported | Hinz et al |

*The only case reporting complete resolution. All other cases noted marked improvement but did not document complete resolution.

mo, Month; Ref, references; yr, years.
regardless of the patient’s age or chronicity of symptoms (Table 1). Most pediatric cases of tumid lupus erythematosus require oral antimalarials in addition to or in place of topical treatment (Supplementary Table 1, available via Mendeley at https://data.mendeley.com/datasets/xgwy7bfrrc/1). Our case demonstrates the potential utility of dapsone for the scenario in which antimalarial therapy is poorly tolerated.

The unilateral blaschkolinear distribution is suggestive of underlying mosaicism on the genetic or epigenetic level, leading to the strikingly sharp demarcations of disease along presumed developmental lines. This model would provide the basis for discovery of pathogenic genes in tumid lupus erythematosus (ie, by genome-wide comparison of affected vs normal tissue), as well as future targeted therapy.

Conflicts of interest
None disclosed.

REFERENCES
1. Kuhn A, Bein D, Bonsmann G. The 100th anniversary of lupus erythematosus tumidus. Autoimmun Rev. 2009;8(6):441-448.
2. Pacheco TR, Spates ST, Lee LA. Unilateral tumid lupus erythematosus. Lupus. 2002;11(6):388-391.
3. Vaughn OLA, Siegel DH, Chiu YE, et al. Clinical and histologic presentation of pediatric reactive granulomatous dermatitis. Pediatr Dermatol. 2020;37(3):498-503.
4. Sonntag M, Lehmann P, Megahed M, Ruzicka T, Kuhn A. Lupus erythematosus tumidus in childhood. Report of 3 patients. Dermatology. 2003;207(2):188-192.
5. Aguirre LM, Toro AM, del Río DY, Ruiz AC. Lupus erythematosus tumidus in childhood treated with antimalarials. CES Med. 2018;32(2):141-149.
6. Mostow EN, Reedy MS. A unique presentation of lupus erythematosus tumidus in an adolescent boy. Cutis. 2019; 104(1):E6-E7.
7. Guleva D, Dourmishev L, Botev I, Miteva L. Lupus erythematosus tumidus in an adolescent with beta thalassemia minor successfully controlled with hydroxychloroquine. Dermatol Ther. 2020;33(6):e14394.
8. Kim GH, Jeong JH, Hong JS, Lee SH, Lee AY. A rare case of tumid lupus erythematosus with unilateral linear distribution in a young child. Dermatol Sin. 2020;38(4):225-227.
9. Hinz T, Hornung T, Wenzel J, Bieber T. Lupus tumidus following the lines of Blaschko. Int J Dermatol. 2013;52(12):1615-1617.
10. Bouzit N, Grezard P, Wolf F, Balme B, Perrot H. Linear cutaneous lupus erythematosus in an adult. Dermatology. 1999;199:60-62.
11. Jin H, Zhang G, Zhou Y, Chang C, Lu Q. Old lines tell new tales: Blaschko linear lupus erythematosus. Autoimmun Rev. 2016; 15(4):291-306.
12. Kuhn A, Aberer E, Bata-Csörgő Z, et al. S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2017;31(3):389-404.